Beyond THC: The new generation of cannabinoid designer drugs

Frontiers in Behavioral Neuroscience

Volumn , Issue SEPTEMBER, 2011, Pages

  Fattore, Liana ^a,b   Fratta, Walter ^b  

^a CNR   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Addiction; Cannabimimetics; Designer drugs; Herbal blends; Internet; Natural highs; Spice; Synthetic cannabinoids

Indexed keywords

(2 3 HYDROXYCYCLOHEXYL 5 (2 METHYLOCTAN 2 YL)PHENOL); (NAPHTHALEN 1 YL (1 BUTYLINDOL 3 YL)METHANONE); 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (1 NAPHTHOYL) 1 PENTYLINDOLE; [(1 (5 FLUOROPHENYL) 3 (2 IODOBENZOYL)INDOLE)]; [(4 METHOXYPHENYL) (1 PENTYL 1H INDOL 3 YL)METHANONE]; AM 694; ASARONE; BENZOPHENONE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; CANNABIS; DESIGNER DRUG; DEXANABINOL; DRONABINOL; GENERIC DRUG; HARMALINE; HARMINE; HERBACEOUS AGENT; INDOLE DERIVATIVE; JWH 019; JWH 073; JWH 250; MITRAGYNINE; MYRISTICIN; NABILONE; O NORTRAMADOL; OLEAMIDE; OPIATE; PSYCHOTROPIC AGENT; RCS 4; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANXIETY; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CANNABIS SMOKING; CHEMICAL STRUCTURE; COGNITIVE DEFECT; DRUG ABUSE; DRUG MIXTURE; DRUG SCREENING; EMOTION; GASTROINTESTINAL SYMPTOM; HERBAL MEDICINE; HUMAN; IMMUNOASSAY; INCENSE; INTERNET; LAW; NAUSEA AND VOMITING; NONHUMAN; PSYCHOSIS; URINALYSIS; WITHDRAWAL SYNDROME;

EID: 84855507862     PISSN: 16625153     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnbeh.2011.00060     Document Type: Article

References (119)

1. Advisory Council on the Misuse of Drugs (ACMD). (2009). Consideration of the Major Cannabinoid Agonists. London: Home Office.
2. Air Force Times. (2011). AF Using Urine Tests to Detect "Spice" Use. Available at: http://www.airforcetimes.com/news/2011/03/air-force-using-urinetests-for-spice-031211w/ [accessed August 9, 2011].
3. Alger, B. E., and Kim, J. (2011). Supply and demand for endo-cannabinoids. Trends Neurosci. 3, 304-315.
4. Arndt, T., Claussen, U., Güssregen, B., Schröfel, S., Stürzer, B., Werle, A., and Wolf, G. (2011). Kratom alkaloids and O-desmethyltramadol in urine of a "Krypton" herbal mixture consumer. Forensic Sci. Int. 208, 47-52.
5. Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., and Moffitt, T. E. (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325, 1212-1213.
6. Atwood, B. K., Huffman, J., Straiker, A., and Mackie, K. (2010). JWH018, a common constituent of "spice" herbal blends, is a potent and efficacious cannabinoid CB1 receptor agonist. Br. J. Pharmacol. 160, 133-140.
7. Atwood, B. K., Lee, D., Straiker, A., Widlanski, T. S., and Mackie, K. (2011). CP47,497-C8 and JWH073, commonly found in "spice" herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur. J. Pharmacol. 659, 139-145.
8. Aung, M. M., Griffin, G., Huffman, J. W., Wu, M., Keel, C., Yang, B., Showalter, V. M., Abood, M. E., and Martin, B. R. (2000). Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding. Drug Alcohol Depend. 60, 133-140.
9. Aurazendoctor. (2009). Make Your Own Herbal Spice Gold Smoke Blends eBook CD, eBay, ID Number: 270362517411. Available at: http://cgi.ebay.com/Make-Your-Own-Herbal-Spice-Gold-Smoke-BlendseBook-CD_W0QQitemZ270362517411 [accessed March 24, 2009].
10. Auwärter, V., Dresen, S., Weinmann, W., Müller, M., Pütz, M., and Ferreirós, N. (2009). "Spice" and other herbal blends: harmless incense or cannabinoid designer drugs? J. Mass Spectrom. 44, 832-837.
11. Banerji, S., Deutsch, C. M., and Bronstein, A. C. (2010). Spice ain't so nice. Clin. Toxicol. (Phila.) 48, 632.
12. Bebarta, V. S., Varney, S., and Sessions, D. (2010). Spice: a new "legal" herbal mixture abused by young active duty military personnel. Clin. Toxicol. (Phila.) 48, 632.
13. Benford, D. M., and Caplan, J. P. (2011). Psychiatric sequelae of spice, k2, and synthetic cannabinoid receptor agonists. Psychosomatics 52, 295.
14. Bergamaschi, M. M., Queiroz, R. H., Chagas, M. H., de Oliveira, D. C., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., Martín-Santos, R., Hallak, J. E., Zuardi, A. W., and Crippa, J. A. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 36, 1219-1226.
15. Beuck, S., Möller, I., Thomas, A., Klose, A., Schlörer, N., Schänzer, W., and Thevis, M. (2011). Structure characterisation of urinary metabolites of the cannabimimetic JWH-018 using chemically synthesised reference material for the support of LCMS/MS-based drug testing. Anal. Bioanal. Chem. 401, 493-505.
16. Boyer, E. W., Shannon, M., and Hibberd, P. L. (2001). Web sites with misinformation about illicit drugs. N. Engl. J. Med. 345, 469-471.
17. Brents, L. K., Reichard, E. E., Zimmerman, S. M., Moran, J. H., Fantegrossi, W. E., and Prather, P. L. (2011). Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 6, e21917. doi: 10.1371/journal.pone.0021917
18. Budney, A. J., and Hughes, J. R. (2006). The cannabis withdrawal syndrome. Curr. Opin. Psychiatry 19, 233-238.
19. Burley, B. (2008). Doctors Worries Over Legal Highs. BBC Newsbeat Oct 7, 2008. Available at: http://news.bbc.co.uk/newsbeat/hi/health/newsid_7656000/7656172.stm [accessed May 3, 2011].
20. Canning, J. C., Ruha, A.-M., Pierce, R., Torrey, M., and Reinhart, S. J. (2010). Severe GI distress after smoking JWH-018. Clin. Toxicol. (Phila.) 48, 618.
21. Chin, C. N., Murphy, J. W., Huffman, J. W., and Kendall, D. A. (1999). The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J. Pharmacol. Exp. Ther. 291, 837-844.
22. Compton, D. R., Johnson, M. R., Melvin, L. S., and Martin, B. R. (1992). Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J. Pharmacol. Exp. Ther. 260, 201-209.
23. Corazza, O., Schifano, F., Farre, M., Deluca, P., Davey, Z., Torrens, M., Demetrovics, Z., Di Furia, L., Flesland, L., Siemann, H., Skutle, A., Van Der Kreeft, P., and Scherbaum, N. (2011). Designer drugs on the internet: a phenomenon out-of-control? The emergence of hallucinogenic drug BromoDragonfly. Curr. Clin. Pharmacol. 6, 125-129.
24. Crippa, J. A., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., Santos Filho, A., Freitas-Ferrari, M. C., McGuire, P. K., Zuardi, A. W., Busatto, G. F., and Hallak, J. E. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J. Psychopharmacol. (Oxford) 25, 121-130.
25. Danish Ministry of Health. (2011). Amendment of executive order on euphoriant substances11 March 2011. Available at: http://laegemiddelstyrelsen.dk/en/servicemenu/product-areas/euphoriantsubstances/nyheder-om-euforiserende-stoffer/amendment-ofexecutive-order-on-euphoria-march2011 [accessed August 8, 2011].
26. Dargan, P. I., Hudson, S., Ramsey, J., and Wood, D. M. (2011). The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in "spice." Int. J. Drug Policy 22, 274-277.
27. Dhawan, K., Dhawan, S., and Sharma, A. (2004). Passiflora: a review update. J. Ethnopharmacol. 94, 1-23.
28. Dowling, G., and Regan, L. (2011). A method for CP 47, 497 a synthetic non-traditional cannabinoid in human urine using liquid chromatography tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879, 253-259.
29. Dresen, S., Ferreirós, N., Pütz, M., Westphal, F., Zimmermann, R., and Auwärter, V. (2010). Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J. Mass Spectrom. 45, 1095-1232.
30. Dresen, S., Kneisel, S., Weinmann, W., Zimmermann, R., and Auwärter, V. (2011). Development and validation of a liquid chromatographytandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. J. Mass Spectrom. 46, 163-171.
31. Drug Enforcement Administration. (2011). Schedules of Controlled Substances: Temporary Placement of Five Synthetic Cannabinoids Into Schedule I. Federal Register 2011, 76(40). Available at: http://www.deadiversion.usdoj.gov/fed_regs/rules/2011/fr0301.htm [accessed August 8, 2011].
32. Drug Policy Alliance. (2011). Legislation to Ban K2/Spice, "Bath Salts" and Other Synthetic Drugs Sailing Through Congress Today. Available at: http://www.drugpolicy.org/news/2011/07/legislation-ban-k2spicebath-salts-and-other-synthetic-drugs-sailing-through-congress-t [accessed August 9, 2011].
33. Drugs-Forum. (2011). Herbal incense recipe (JWH-073 + RCS-4). Available at: http://www.drugsforum.com/forum/showthread.php?t=146867 [accessed June 3, 2011].
34. Early Warning System. (2009). Available at: http://www.emcdda.europa.eu/themes/new-drugs/early-warning [accessed October 23, 2009].
35. Ernst, L., Schiebel, H. M., Theuring, C., Lindigkeit, R., and Beuerle, T. (2011). Identification and characterization of JWH-122 used as new ingredient in "spice-like" herbal incenses. Forensic Sci. Int. 208, 31-35.
36. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).(2009).Understanding the "Spice" Phenomenon. Lisbon: EMCDDA; 2009. Available at: http://www.emcdda.europa.eu/html.cfm/index90917EN.html [accessed April 23, 2011].
37. Every-Palmer, S. (2010). Warning: legal synthetic cannabinoid-receptor agonists such as JWH018 may precipitate psychosis in vulnerable individuals. Addiction 105, 1859-1860.
38. Every-Palmer, S.(2011). Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend. 117, 152-157.
39. Fedorova, I., Hashimoto, A., Fecik, R. A., Hedrick, M. P., Hanus, L. O., Boger, D. L., Rice, K. C., and Basile, A. S. (2001). Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems. J.Pharmacol. Exp. Ther.299, 332-342.
40. Ferrari, F., Ottani, A., and Giuliani, D. (2000).Inhibitory effects of the cannabinoid agonist HU 210 on rat sexual behaviour. Physiol. Behav. 69, 547-554.
41. Ferrari, F., Ottani, A., Vivoli, R., and Giuliani, D. (1999). Learning impairment produced in rats by the cannabinoid agonist HU 210 in a water-maze task. Pharmacol. Biochem. Behav. 64, 555-561.
42. Fisher, W.G. (2010). Inhaled Incense "K2" May Cause Heart Damage. Available at: http://drwes.blogspot.com/2010/08/inhaled-incense-k2may-cause-heart.html? [accessed June 2, 2011].
43. Fortunato, J. J., Réus, G. Z., Kirsch, T. R., Stringari, R. B., Fries, G. R., Kapczinski, F., Hallak, J. E., Zuardi, A. W., Crippa, J. A., and Quevedo, J. (2010). Effects of beta-carboline harmine on behavioral and physiological parameters observed in the chronic mild stress model: further evidence of antidepressant properties. Brain Res. Bull. 81, 491-496.
44. Fortunato, J. J., Réus, G. Z., Kirsch, T. R., Stringari, R. B., Stertz, L., Kapczinski, F., Pinto, J. P., Hallak, J. E., Zuardi, A. W., Crippa, J. A., and Quevedo, J. (2009). Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 1425-1430.
45. Gay, M. (2010). Synthetic Marijuana Spurs State Bans. In The New York Times, July 10. Available at: http://www.nytimes.com/2010/07/11/us/11k2.html [accessed April 3, 2011].
46. Griffiths, P., Sedefov, R., Gallegos, A., and Lopez, D. (2010). How globalization and market innovation challenge how we think and respond to drug use: "spice" a case study. Addiction 105, 951-953.
47. Grigoryev, A., Savchuk, S., Melnik, A., Moskaleva, N., Dzhurko, J., Ershov, M., Nosyrev, A., Vedenin, A., Izotov, B., Zabirova, I., and Rozhanets, V. (2011). Chromatography-mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879, 1126-1136.
48. Guimarães, F. S., Chiaretti, T. M., Graeff, F. G., and Zuardi, A. W. (1990). Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl.) 100, 558-559.
49. Hammersley, R. (2010). Dangers of banning spice and the synthetic cannabinoid agonists. Addiction 105, 373.
50. Hillebrand, J., Olszewski, D., and Sedefov, R. (2010). Legal highs on the Internet. Subst. Use Misuse 45, 330-340.
51. Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., Mechoulam, R., and Pertwee, R. G. (2002). International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54, 161-202.
52. Hu, X., Primack, B. A., Barnett, T. E., and Cook, R. L. (2011). College students and use of K2: an emerging drug of abuse in young persons. Subst. Abuse Treat. Prev. Policy 6, 16-19.
53. Hudson, S., and Ramsey, J. (2011). The emergence and analysis of synthetic cannabinoids. Drug Test Anal. 3, 466-478.
54. Hudson, S., Ramsey, J., King, L., Timbers, S., Maynard, S., Dargan, P. I., and Wood, D. M. (2010). Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in "herbal high" products. J. Anal. Toxicol. 34, 252-260.
55. Huffman, J. W. (2009). "Cannabimimetic indoles, pyrroles, and indenes: structure-activity relationships and receptor interactions," in The Cannabinoid Receptors, ed. P. H. Reggio (New York, Humana Press), 49-94.
56. Huffman, J. W., Mabon, R., Wu, M. J., Lu, J., Hart, R., Hurst, D. P., Reggio, P. H., Wiley, J. L., and Martin, B. R. (2003). 3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB1 cannabinoid receptor. Bioorg. Med. Chem. 11, 539-549.
57. Huffman, J. W., and Padgett, L. W. (2005). Recent developments in the medicinal chemistry of cannabinomimetic indoles, pyrroles and indenes. Curr. Med. Chem. 12, 1395-1411.
58. Huffman, J. W., Thompson, A. L., Wiley, J. L., and Martin, B. R. (2008). Synthesis and pharmacology of 1deoxy analogs of CP-47,497 and CP-55,940. Bioorg. Med. Chem. 16, 322-335.
59. Huffman, J. W., Zengin, G., Wu, M. J., Lu, J., Hynd, G., Bushell, K., Thompson, A. L., Bushell, S., Tartal, C., Hurst, D. P., Reggio, P. H., Selley, D. E., Cassidy, M. P., Wiley, J. L., and Martin, B. R. (2005). Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg. Med. Chem. 13, 89-93.
60. Jack, A. (2009). The Story of Spice. The Financial Times Online, February 13. Available at: http://www.ft.com/cms/s/2/1721e2da-f8a0-11ddaae8-000077b07658.html [accessed May 5, 2011].
61. Kikura-Hanajiri, R., Uchiyama, N., and Goda, Y. (2011). Survey of current trends in the abuse of psychotropic substances and plants in Japan. Leg. Med. (Tokyo) 13, 109-115.
62. Kronstrand, R., Roman, M., Thelander, G., and Eriksson, A. (2011). Unintentional fatal intoxications with mitragynine and o-desmethyltramadol from the herbal blend krypton. J. Anal. Toxicol. 35, 242-247.
63. Leggett, J. D., Aspley, S., Beckett, S. R., D'Antona, A. M., Kendall, D. A., and Kendall, D. A. (2004). Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br. J. Pharmacol. 141, 253-262.
64. Lindigkeit, R., Boehme, A., Eiserloh, I., Luebbecke, M., Wiggermann, M., Ernst, L., and Beuerle, T. (2009). Spice: a never ending story? Forensic Sci. Int. 191, 58-63.
65. Malone, D. T., Jongejan, D., and Taylor, D. A. (2009). Cannabidiol reverses the reduction in social interaction produced by low dose delta(9)tetrahydrocannabinol in rats. Pharmacol. Biochem. Behav. 93, 91-96.
66. Mackowiak, M., Chocyk, A., Dudys, D., and Wedzony, K. (2009). Activation of CB1 cannabinoid receptors impairs memory consolidation and hippocampal polysialylated neural cell adhesion molecule expression in contextual fear conditioning. Neuroscience 158, 1708-1716.
67. McLachlan, G. (2009). Taking the spice out of legal smoking mixtures. Lancet 374, 600.
68. Missouri Department of Health and Senior Services. (2010). Health Advisory (3.05.10): K2 Synthetic Marijuana Use among Teenagers and Young Adults in Missouri Missouri. Available at: http://health.mo.gov/emergencies/ert/alertsadvisories/index.php [accessed August 8, 2011].
69. Moran, C. L., Le, V. H., Chimalakonda, K. C., Smedley, A. L., Lackey, F. D., Owen, S. N., Kennedy, P. D., Endres, G. W., Ciske, F. L., Kramer, J. B., Kornilov, A. M., Bratton, L. D., Dobrowolski, P. J., Wessinger, W. D., Fantegrossi, W. E., Prather, P. L., James, L. P., Radominska-Pandya, A., and Moran, J. H. (2011). Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal. Chem. 83, 4228-4236.
70. Moreira, F. A., Aguiar, D. C., and Guimarães, F. S. (2006). Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 1466-1471.
71. Müller, H., Sperling, W., Köhrmann, M., Huttner, H. B., Kornhuber, J., and Maler, J. M. (2010). The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr. Res. 118, 309-310.
72. Nakajima, J., Takahashi, M., Seto, T., and Suzuki, J. (2011). Identification and quantitation of cannabimimetic compound JWH-250 as an adulterant in products obtained via the internet. Forensic Toxicol. 29, 51-55.
73. Organised Crime Threat Assessment (OCTA). (2011). Europol Public Information. Available at: http://www.europol.europa.eu/content/publication/octa-2011-euorganised-crime-threat-assessment655 [accessed August 9, 2011].
74. Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br. J. Pharmacol. 153, 199-215.
75. Philipp, A. A., Meyer, M. R., Wissenbach, D. K., Weber, A. A., Zoerntlein, S. W., Zweipfenning, P. G., and Maurer, H. H. (2011). Monitoring of kratom or Krypton intake in urine using GC-MS in clinical and forensic toxicology. Anal. Bioanal. Chem. 400, 127-135.
76. Piggee, C. (2009). Investigating a notso-natural high. Anal. Chem. 81, 3205-3207.
77. Psychonaut Web Mapping Research Group. (2010). Psychonaut Web Mapping Project: Final Report. London: Institute of Psychiatry, King's College London.
78. Raffa, R. B. (2008). Basic pharmacology relevant to drug abuse assessment: tramadol as example. J. Clin. Pharmacol. Ther. 33, 101-108.
79. Rawaf, S., and Schifano, F. (2000). The internet, children, young people and substance misuse: co-ordinated approaches are needed to minimise the use of Ecommerce to obtain drugs and prevent substance misuse. Public Health Med. 2, 96.
80. Robinson, L., Goonawardena, A. V., Pertwee, R. G., Hampson, R. E., and Riedel, G. (2007). The synthetic cannabinoid HU210 induces spatial memory deficits and suppresses hippocampal firing rate in rats. Br. J. Pharmacol. 151, 688-700.
81. Schifano, F., Corazza, O., Deluca, P., Davey, Z., Di Furia, L., Flesland, L., Mannonen, M., Pagani, S., Peltoniemi, T., Pezzolesi, C., Scherbaum, N., Siemann, H., Skutle, A., Torrens, M., and Van Der Kreeft, P. (2009). Psychoactive drug or mystical incense? Overview of the online available information on spice products. Int. J. Cult. Ment. Health 2, 137-144.
82. Schifano, F., Deluca, P., Baldacchino, A., Peltoniemi, T., Scherbaum, N., Torrens, M., Farre, M., Flores, I., Rossi, M., Eastwood, D., Guionnet, C., Rawaf, S., Agosti, L., Di Furia, L., Brigada, R., Majava, A., Siemann, H., Leoni, M., Tomasin, A., Rovetto, F., and Ghodse, A. H. (2006). Drugs on the web; the psychonaut 2002 EU project. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 640-646.
83. Schifano, F., Leoni, M., Martinotti, G., Rawaf, S., and Rovetto, F. (2003). Importance of cyberspace for the assessment of the drug abuse market: preliminary results from the psychonaut 2002 project. Cyberpsychol. Behav. 6, 405-410.
84. Schmidt, M. M., Sharma, A., Schifano, F., and Feinmann, C. (2011). "Legal highs" on the net-evaluation of UKbased Websites, products and product information. Forensic Sci. Int. 206, 92-97.
85. Schneir, A. B., Cullen, J., and Ly, B. T. (2011). "Spice" girls: synthetic cannabinoid intoxication. J. Emerg. Med. 40, 296-299.
86. Seely, K. A., Prather, P. L., James, L. P., and Moran, J. H. (2011). Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol. Interv. 11, 36-51.
87. Simmons, J., Cookman, L., Kang, C., and Skinner, C. (2011a). Three cases of "spice" exposure. Clin. Toxicol. (Phila.) 49, 431-433.
88. Simmons, J. R., Skinner, C. G., Williams, J., Kang, C. S., Schwartz, M. D., and Wills, B. K. (2011b). Intoxication from smoking "spice." Ann. Emerg. Med. 57, 187-188.
89. Sobolevsky, T., Prasolov, I., and Rodchenkov, G. (2010). Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci. Int. 200, 141-147.
90. Steup, C. (2009). Drugs Shipped as Incense Seized as DHL. Wilmington News Journal. Available at: http://usualredant.de/drogen/download/analyse-thc-pharm-Spicejwh-018.pdf [accessed March 4, 2009].
91. Teske, J., Weller, J.P., Fieguth, A., Rothämel, T., Schulz, Y., and Tröger, H.D. (2010). Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878, 265-269.
92. Thakur, G. A., Tichkule, R., Bajaj, S., and Makriyannis, A. (2009). Latest advances in cannabinoid receptor agonists. Expert Opin. Ther. Pat. 19, 1647-1673.
93. Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., and Pertwee, R. G. (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol. 150, 613-623.
94. Uchiyama, N., Kawamura, M., KikuraHanajiri, R., and Goda, Y. (2011a). Identification and quantitative analyses of two cannabimimetic phenylacetylindoles, JWH-251 and JWH-250, and four cannabimimetic naphthoylindoles, JWH-081, JWH-015, JWH-200 and JWH073, as designer drugs in illegal products. Forensic Toxicol.29, 25-37.
95. Uchiyama, N., Kikura-Hanajiri, R., Matsumoto, N., Huang, Z. L., Goda, Y., and Urade, Y. (2011b). Effects of synthetic cannabinoids on electroencephalogram power spectra in rats. Forensic Sci. Int. 1. doi: 10.1016/j.forsciint.2011.05.005. [Epub ahead of print].
96. Uchiyama, N., Kikura-Hanajiri, R., Kawahara, N., and Goda, Y. (2009a). Identification of a cannabimimetic indole as a designer drug in a herbal product. Forensic Toxicol. 27, 61-66.
97. Uchiyama, N., Kikura-Hanajiri, R., Kawahara, N., Haishima, Y., and Goda, Y. (2009b). Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem. Pharm. Bull. 57, 439-441.
98. Uchiyama, N., Kikura-Hanajiri, R., Ogata, J., and Goda, Y. (2010). Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci. Int. 198, 31-38.
99. UK Statutory Instrument. (2009). No. 3209. Dangerous Drugs. The Misuse of Drugs Act 1971 (Amendment) Order 2009. Available at: http://www.opsi.gov.uk/si/si2009/pdf/uksi20093209en.pdf [accessed August 13, 2010].
100. Uniform Code of Military Justice (UCMJ). (2011). UCMJ BansSpice. Available at: http://court-martial.com/spice/ [accessed August 9, 2011].
101. United Nations Office on Drugs and Crime (UNODC). (2011). World Drug Report,2010. Availableat: http://www.idpc.net/publications/unodc-world-drugreport-2011 [accessed August 9, 2011].
102. United States Drug Enforcement Administration, Office of Forensic Sciences(2009)."Spice"-Plant Material(S) Laced With Synthetic Cannabinoids or Cannabinoid Mimicking Compounds. Microgram Bulletin 42(3). Available at: http://www.justice.gov/dea/programs/forensicsci/microgram/mg0309/mg0309.html [accessed June 1, 2010].
103. US Department of Justice Drug Enforcement Administration Drugs and Chemicals of Concern. (2010). Spice cannabinoids. Available at: http://www.deadiversion.usdoj.gov/drugs_concern/spice/index.html [accessed April 23, 2011].
104. Vardakou, I., Pistos, C., and Spiliopoulou, C. H. (2010). Spice drugs as a new trend: mode of action, identification and legislation. Toxicol. Lett. 197, 157-162.
105. Vardakou, I., Pistos, C., and Spiliopoulou, C. H. (2011). Drugs for youth via Internet and the example of mephedrone. Toxicol. Lett. 201, 191-195.
106. Vearrier, D., and Osterhoudt, K. C. (2010). A teenager with agitation: higher than she should have climbed. Pediatr. Emerg. Care 26, 462-465.
107. Weissman, A., Milne, M., and Melvin, M. S. Jr. (1982). Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol. J. Pharmacol. Exp. Ther. 223, 516-523.
108. Westphal, F., Junge, T., Sonnichsen, F., Rosner, P., and Schaper, J. (2010). Ein neuer Wirkstoff in SPICE-artigen Kräutermischungen: Charakterisierung von JWH250, seinen Methyl-und Trimethylsilylderivaten (A new compound in herbal mixtures: characterisation of JWH-250, its methyland trimethylsilyl-derivatives). Toxichem. Krimtech. 77, 46-58.
109. Westphal,F.,Sönnichsen,F. D., and Thiemt, S.(2011). Identificationof1-butyl-3-(1(4-methyl)naphthoyl)indole in a herbal mixture. Forensic Sci. Int. doi: 10.1016/j.forsciint.2011.03.031. [Epub ahead of print].
110. Wiley, J. L., Compton, D. R., Dai, D., Lainton, J. A., Phillips, M., Huffman, J. W., and Martin, B. R. (1998). Structure-activity relationships of indoleand pyrrole-derived cannabinoids. J. Pharmacol. Exp. Ther. 285, 995-1004.
111. Wintermeyer, A., Möller, I., Thevis, M., Jübner, M., Beike, J., Rothschild, M. A., and Bender, K. (2010). In vitro phase I metabolism of the synthetic cannabimimetic JWH018. Anal. Bioanal. Chem. 398, 2141-2153.
112. World Anti-Doping Agency (WADA). (2011). Available at: http://www.wada-ama.org/rtecontent/document/ 2010_Prohibited_List_FINAL_EN_Web.pdf [accessed April 5, 2011].
113. Zawilska, J. B. (2011). "Legal highs" new players in the old drama. Curr. Drug Abuse Rev. 4, 122-130.
114. Zhang, Q., Ma, P., Cole, R. B., and Wang, G. (2006). Identification of in vitro metabolites of JWH-015, an aminoalkylindole agonist for the peripheral cannabinoid receptor (CB2) by HPLC-MS/MS. Anal. Bioanal. Chem. 386, 1345-1355.
115. Zimmermann, U. S., Winkelmann, P. R., Pilhatsch, M., Nees, J. A., Spanagel, R., and Schulz, K. (2009). Withdrawal phenomena and dependence syndrome after the consumption of "spice gold." Dtsch. Artzebl. Int. 106, 464-467.
116. Zuardi, A. W., Crippa, J. A., Hallak, J. E., Moreira, F. A., and Guimarães, F. S. (2006). Cannabidiol, a cannabis sativa constituent, as an antipsychotic drug. Braz. J. Med. Biol. Res. 39, 421-429.
117. Zuardi, A. W., Shirakawa, I., Finkelfarb, E., and Karniol, I. G. (1982). Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl.) 76, 245-250.
118. Zuba, D., Byrska, B., and Maciow, M. (2011). Comparison of "herbal highs" composition. Anal. Bioanal. Chem. 400, 119-126.
119. Zullino, D. F., Rathelot, T., and Khazaal, Y. (2007). Cannabis and psychosis. Lancet 370, 15-40.